Chronic Lyme

The phrase chronic Lyme covers two groups with almost nothing in common except suffering. The first: patients with documented, treated Lyme disease who remain unwell — post-treatment Lyme disease syndrome (PTLDS), with fatigue, musculoskeletal pain and cognitive difficulty persisting six months or more, affecting a meaningful minority (estimates commonly 5-15%) of treated patients; this syndrome is real, recognised by mainstream infectious-disease medicine, and biologically plausible via immune and autonomic mechanisms shared with post-viral conditions. The second: people diagnosed with chronic Lyme despite no reliable evidence of ever having had the infection — often via unvalidated laboratory tests or symptom checklists so broad they capture half of any waiting room. Conflating the two is the engine of the entire controversy: the first population deserves recognition and research; the second deserves accurate diagnosis of what they actually have.

The central clinical claim — that persistent symptoms reflect ongoing infection requiring prolonged antibiotics — was tested in four NIH-funded randomised placebo-controlled trials of extended intravenous and oral antibiotic retreatment. The results were consistent: no sustained, clinically meaningful benefit over placebo, with real trial-documented harms including intravenous-line sepsis; European trials of longer oral regimens agreed. This is not an evidence gap — it is among the better-answered questions in infectious disease, which is why every major guideline recommends against long-term antibiotics for persistent post-Lyme symptoms. Case reports of harm from the practice anyway include catheter infections, C. difficile colitis, gallbladder disease from ceftriaxone, and deaths. The treatments fail their own hypothesis test and hurt people; that conclusion does not dismiss the symptoms — it protects the patients.

The commercial chronic-Lyme ecosystem runs on laboratories offering in-house tests with interpretation criteria that dramatically inflate positives — non-standard Western blot band readings, lymphocyte transformation tests, and other assays that regulators and public-health agencies have explicitly warned produce results with no established clinical meaning. Add practitioners (self-described Lyme-literate) diagnosing on symptom clusters — fatigue, brain fog, joint pain — that overlap with dozens of common conditions, and the predictable output is a population certain they harbour a hidden infection, primed for open-ended treatment subscriptions. The cruellest cost is missed diagnosis: case series document patients whose multiple sclerosis, lupus, sleep apnoea, depression, cancers and thyroid disease went untreated for years under a chronic-Lyme label. A diagnosis that explains everything and can be neither confirmed nor refuted is not a diagnosis; it is a business model.

The chronic-Lyme world grew in soil mainstream medicine tilled: patients with genuine persistent symptoms were too often dismissed, disbelieved or discharged with normal tests and no plan — the same institutional failure that long COVID and ME/CFS patients document — and the alternative ecosystem offered what clinics did not: belief, time, an explanation and a plan. Tick-borne illness also carries real diagnostic hazards that fuel distrust: early Lyme serology is genuinely insensitive, co-infections exist, and clinicians in low-incidence areas miss real cases. The honest synthesis is uncomfortable for both camps: the activist world is right that the suffering is real and was disrespected, wrong about the mechanism and the treatments; institutional medicine is right about the trials, and owns the vacuum of care that made pseudo-explanations competitive.

Legitimate research on persistent post-Lyme symptoms is converging with the wider post-acute infection field: no reproducible evidence of viable ongoing infection in treated patients (residual antigenic debris is not the same thing); signals of immune dysregulation, autonomic dysfunction and central sensitisation overlapping with long COVID and ME/CFS; and trial-supported management drawn from those fields — graded activity where tolerated, sleep and autonomic care, pain and cognitive rehabilitation, and treatment of co-occurring depression or anxiety as components rather than dismissals. The strategic prize is shared: post-acute infection syndromes studied together, with Lyme as one trigger among several, is where the mechanism and the therapies will come from — a research programme that requires exactly the accurate case definitions the commercial label destroys.

If you have persistent symptoms after treated Lyme: your illness is real and named — seek care framed around post-treatment syndrome and rehabilitation, not repeat antibiotics, which four trials show do not help and can seriously harm. If you have chronic symptoms and a positive result from a specialty Lyme laboratory: insist on validated two-tier testing and a full differential diagnosis before accepting the label — the alternatives (thyroid, sleep, autoimmune, mental health, other infections) are individually more likely and mostly more treatable. Red flags for any clinic: guaranteed-positive testing, everyone has Lyme framing, open-ended antibiotic or supplement protocols, and hostility to second opinions. And for prevention where you live: tick checks, prompt removal and early treatment of documented infection remain the interventions with actual evidence.